1. Home
  2. OGC vs ERAS Comparison

OGC vs ERAS Comparison

Compare OGC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OceanaGold Corporation Common Shares

OGC

OceanaGold Corporation Common Shares

SELL

Current Price

$26.03

Market Cap

5.9B

Sector

N/A

ML Signal

SELL

Logo Erasca Inc.

ERAS

Erasca Inc.

SELL

Current Price

$15.11

Market Cap

6.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
OGC
ERAS
Founded
1990
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
6.3B
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
OGC
ERAS
Price
$26.03
$15.11
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
★ $24.11
AVG Volume (30 Days)
462.3K
★ 4.7M
Earning Date
11-04-2026
11-12-2026
Dividend Yield
★ 1.34%
N/A
EPS Growth
N/A
★ 36.23
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$43.06
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$21.90
$2.71
52 Week High
$31.90
$24.28

Technical Indicators

Market Signals
Indicator
OGC
ERAS
Relative Strength Index (RSI) 46.86 50.15
Support Level $25.58 $13.18
Resistance Level $27.09 $15.71
Average True Range (ATR) 0.95 1.23
MACD 0.17 0.15
Stochastic Oscillator 44.01 46.34

Price Performance

Historical Comparison
OGC
ERAS

About OGC OceanaGold Corporation Common Shares

OceanaGold Corp is a growing intermediate gold and copper producer committed to safely and responsibly maximizing the generation of Free Cash Flow from its operations and delivering robust returns for its shareholders. It has a portfolio of four operating mines: the Haile Gold Mine in the United States of America; the Didipio Mine in the Philippines; and the Macraes and Waihi operations in New Zealand. The company generates key revenue from Haile mines.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: